JPMorgan Chase & Co. cut shares of Brenntag (OTCMKTS:BNTGY – Get Rating) from an overweight rating to a neutral rating in a research report released on Tuesday, The Fly reports.
BNTGY has been the topic of several other research reports. Morgan Stanley initiated coverage on shares of Brenntag in a research note on Wednesday, January 25th. They issued an overweight rating on the stock. Jefferies Financial Group initiated coverage on shares of Brenntag in a research report on Tuesday, February 7th. They issued a hold rating on the stock. The Goldman Sachs Group initiated coverage on shares of Brenntag in a research note on Tuesday, January 10th. They issued a buy rating for the company. Finally, Citigroup upgraded shares of Brenntag from a neutral rating to a buy rating in a research note on Wednesday, February 15th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Brenntag currently has an average rating of Moderate Buy and an average price target of $99.00.
Brenntag Stock Performance
Brenntag stock opened at $14.59 on Tuesday. The firm has a 50-day moving average price of $14.87 and a 200-day moving average price of $13.41. Brenntag has a 12-month low of $10.37 and a 12-month high of $16.93.
About Brenntag
Brenntag SE engages in the production and distribution of chemicals. It operates through the following geographical segments: Brenntag Essentials and Brenntag Specialties. The Brenntag Essentials segment markets a portfolio of process chemicals to the industries and applications. The Brenntag Specialties segment focuses on selling ingredients and value-added services to the selected industries Nutrition, Pharma, Personal Care/HI&I(Home, Industrial & Institutional), Material Science (Coatings & Constructions, Polymers, Rubber), Water Treatment and Lubricants.
Read More
- Get a free copy of the StockNews.com research report on Brenntag (BNTGY)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Brenntag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brenntag and related companies with MarketBeat.com's FREE daily email newsletter.